异基因造血干细胞移植在骨髓增生异常综合征中的应用  

Application of allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome

作　　者：李芳 李建勇[1] 缪扣荣[1] Li Fang;Li Jianyong;Miao Kourong(Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院,江苏省人民医院血液科,210029

出　　处：《白血病．淋巴瘤》2022年第7期445-448,共4页Journal of Leukemia & Lymphoma

摘　　要：骨髓增生异常综合征(MDS)是一种起源于造血干细胞、以造血功能异常、高风险向髓系白血病转化为特征的异质性髓系肿瘤。异基因造血干细胞移植(allo-HSCT)对于MDS患者具有巨大的治疗潜力,是唯一能治愈MDS的有效方法。疾病类型、疾病预后分层、不同治疗时机、预处理强度及移植后复发等因素均影响着患者移植后的生存。明确移植适应证,灵活在不同时机纳入移植患者,选择合适的预处理方案,监测移植后复发情况对于改善MDS患者移植预后具有至关重要的作用。文章将围绕这些方面对allo-HSCT在MDS患者中的应用进展进行综述。Myelodysplastic syndrome(MDS)is a kind of heterogeneous myeloid tumor that originates from hematopoietic stem cells and is characterized by hematopoietic dysfunction and high risk of transformation into myeloid leukemia.Allogeneic hematopoietic stem cell transplantation(allo-HSCT)has a great therapeutic potential for MDS patients and is the only effective option to cure MDS.Factors such as disease type,disease prognosis stratification,timing of transplantation,the intensity of preconditioning and relapse after transplantation all affect the survival of patients after transplantation.It is of great importance to clarify transplantation indications,flexibly choose patients at different times,select appropriate conditioning regimens and monitor the relapse after transplantation for improving the prognosis of MDS patients after transplantation.This article reviews the current progress of the application of allo-HSCT in MDS patients from these aspects.

关 键 词：造血干细胞移植 骨髓增生异常综合征 移植预处理 预后 

分 类 号：R551.3[医药卫生—血液循环系统疾病]